文献速递临床试验与 GCP流行病学与生物统计

延长早期乳腺癌内分泌治疗时长:对22031例已接受至少5年内分泌治疗的绝经后女性进行的12项芳香化酶抑制剂随机试验的患者水平Meta分析

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
PubMed 文献 · Lancet · 2025-01-01

该个体患者数据Meta分析纳入12项随机试验的22031例已完成至少5年内分泌治疗的绝经后早期乳腺癌女性,比较后续芳香化酶抑制剂治疗(AIT)与不再治疗。分配至AIT使复发率降低27%(RR 0.73,95%CI 0.67-0.80,p<0.0001),但5年骨折风险增加(RR 1.35,95%CI 1.13-1.61,p=0.0009)。

要点

  • 后续AIT较不再治疗降低复发率27%(RR 0.73,95%CI 0.67-0.80,p<0.0001)。
  • 既往接受过AIT者再行5年AIT降低复发(RR 0.71)和远处复发(RR 0.73)。
  • 5年AIT增加5年骨折风险(RR 1.35,95%CI 1.13-1.61,p=0.0009;4.6% vs 3.4%)。

核心结论

  • 分配至再行5年AIT使后续远处复发率降低约四分之一,尽管存在大量不依从。
  • 需要更长时间随访才能直接评估对死亡率的影响。

研究设计与样本

  • 对12项随机试验进行个体患者数据Meta分析,纳入22031例已完成至少5年他莫昔芬、AIT或他莫昔芬后AIT的绝经后女性。
  • 比较后续AIT与不再辅助治疗,主要结局为浸润性乳腺癌复发、乳腺癌死亡、其他原因死亡和全因死亡。
  • 采用意向性治疗分析,按年龄、淋巴结状态和试验分层,并在非相关原因死亡时删失,计算事件率比(RR)。

主要发现

  • 分配至AIT较不再治疗使复发率降低27%(RR 0.73,95%CI 0.67-0.80,p<0.0001)。
  • 既往仅接受他莫昔芬者较既往接受过部分AIT者复发降低更明显,5年AIT试验较2-3年AIT试验复发降低更明显。
  • 既往接受过部分AIT后,分配至再行5年AIT(试验治疗分组后中位随访8.1年,IQR 6.0-10.0)降低复发(RR 0.71,95%CI 0.61-0.81,p<0.0001;诊断后第5年至第15年风险11.6% vs 15.2%)和远处复发(RR 0.73,95%CI 0.61-0.88,p=0.0010;6.6% vs 8.6%)。
  • 乳腺癌死亡率降低未达统计学显著(RR 0.90,95%CI 0.70-1.15,p=0.40;4.4% vs 5.0%)。
  • 肿瘤特征对第5年至第15年复发比例降低无明确影响,10年 vs 5年AIT的绝对复发降低在淋巴结阳性(风险16.3% vs 20.1%)大于淋巴结阴性(9.1% vs 11.8%)。

关键数值与推荐

  • 复发率降低:RR 0.73(95%CI 0.67-0.80),p<0.0001。
  • 既往部分AIT后再行5年AIT:复发RR 0.71(95%CI 0.61-0.81),p<0.0001;远处复发RR 0.73(95%CI 0.61-0.88),p=0.0010;乳腺癌死亡RR 0.90(95%CI 0.70-1.15),p=0.40。
  • 5年骨折风险:RR 1.35(95%CI 1.13-1.61),p=0.0009;4.6% vs 3.4%。
  • 不依从:进一步AIT组39.0% vs 安慰剂组37.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 不依从分配治疗普遍存在(进一步AIT组39.0% vs 安慰剂组37.6%)。
  • 需要更长时间随访才能直接评估对死亡率的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In postmenopausal women with oestrogen receptor-positive early breast cancer, 5 years of adjuvant tamoxifen substantially reduces 15-year recurrence and mortality; aromatase inhibitor treatment (AIT) is even more effective. We assess the effects of further AIT among women recurrence-free after at least 5 years of endocrine therapy. METHODS: We conducted individual patient data meta-analyses of 12 randomised trials, including 22 031 women who had completed at least 5 years of tamoxifen, AIT, or tamoxifen then AIT, comparing subsequent AIT versus no further adjuvant therapy. Primary outcomes were recurrence of invasive breast cancer (local, distant, or new contralateral), breast cancer mortality, mortality from other causes, and all-cause mortality. Intention-to-treat analyses (irrespective of allocation adherence and stratified by age, nodal status, and trial, and censored at death from unrelated causes) yielded event rate ratios (RRs). FINDINGS: Allocation to AIT versus no further treatment reduced recurrence rates by 27% (RR 0·73 [95% CI 0·67-0·80], p<0·0001). This reduction was greater after previous tamoxifen alone than after some previous AIT, and greater in trials of 5 years of AIT versus no further AIT than in trials of 2-3 years of AIT versus no further AIT. After some previous AIT, allocation to 5 further years of AIT (with median 8·1 years [IQR 6·0-10·0] follow-up after trial treatments diverged) reduced both recurrence (RR 0·71 [0·61-0·81], p<0·0001; risk from year 5 to year 15 after diagnosis 11·6% vs 15·2%) and distant recurrence (RR 0·73 [0·61-0·88], p=0·0010; 6·6% vs 8·6%); breast cancer mortality was reduced non-significantly (RR 0·90 [0·70-1·15], p=0·40; 4·4% vs 5·0%). Tumour characteristics had no definite effects on the proportional recurrence reductions from year 5 to year 15, so the absolute recurrence reduction with 10 years vs 5 years AIT was greater for node-positive (risk 16·3% vs 20·1%) than for node-negative disease (9·1% vs 11·8%). Allocation to 5 further years of AIT increased 5-year bone fracture risk (RR 1·35 [1·13-1·61], p=0·0009; 4·6% vs 3·4%). Non-adherence to allocated treatment was widespread (39·0% further AIT vs 37·6% placebo in the placebo-controlled trials). INTERPRETATION: Allocation to 5 further years of AIT reduced subsequent distant recurrence rates by about a quarter despite substantial non-adherence. Longer follow-up would have been needed to help assess directly any effects on mortality. FUNDING: Cancer Research UK and Breast Cancer Research Foundation.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy. Lancet. 2025. PMID: 40783288. doi:10.1016/S0140-6736(25)01013-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。